Evidence map›Paper›PMID 25467439›Full record

ArticlemBio2014

Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation.

Luiz Gustavo Gardinassi, Viktoria Dotz, Agnes Hipgrave Ederveen, Roque Pacheco de Almeida, Carlos Henrique Nery Costa, Dorcas Lamounier Costa, Amélia Ribeiro de Jesus, Oleg A Mayboroda, Gustavo Rocha Garcia, Manfred Wuhrer and 1 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Article
  3. Leishmaniasis.Nature reviews. Disease primers · 2025
    Review
  4. Article
  5. The Human BloodJACS Au · 2024
    Review
  6. Article
  7. Total serumiScience · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Immunoglobulin G Glycosylation in Diseases.Experientia supplementum (2012) · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Luiz Gustavo GardinassiDepartamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Viktoria DotzDivision of Bioanalytical Chemistry, VU University Amsterdam, Amsterdam, The Netherlands.
Agnes Hipgrave EderveenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Roque Pacheco de AlmeidaDepartamento de Medicina, Universidade Federal de Sergipe, Aracajú, Brazil.
Carlos Henrique Nery CostaDepartamento de Medicina Comunitária, Instituto de Doenças Tropicais Natan Portela, Universidade Federal do Piauí, Teresina, Brazil.
Dorcas Lamounier CostaDepartamento de Medicina Comunitária, Instituto de Doenças Tropicais Natan Portela, Universidade Federal do Piauí, Teresina, Brazil.
Amélia Ribeiro de JesusDepartamento de Medicina, Universidade Federal de Sergipe, Aracajú, Brazil.
Oleg A MayborodaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Gustavo Rocha GarciaDepartamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Manfred Wuhrerm.wuhrer@lumc.nl imsantos@fmrp.usp.br.
Isabel Kinney Ferreira de Miranda SantosDepartamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil m.wuhrer@lumc.nl imsantos@fmrp.usp.br.
Netherlands Metabolomics Centre · NLUniversidade de São Paulo · BRUniversidade Federal de Sergipe · BRUniversidade Federal do Piauí · BRLeiden University Medical Center · NLUniversidade de Ribeirão Preto · BRVrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledVisceral leishmaniasis (VL) has a high fatality rate if not treated; nevertheless, the majority of human infections with the causative agent, Leishmania infantum chagasi, are asymptomatic. Although VL patients often present with increased levels of serum immunoglobulins, the contribution of antibodies to resistance or progression to disease remains unknown. Effector and regulatory functions of antibodies rely on their interactions with type I and II Fc receptors, and these interactions are tuned by the patterns of antibody Fc N-glycosylation. In view of these facts, we applied a robust method of IgG Fc N-glycopeptide profiling of serum samples from 187 patients with VL, 177 asymptomatic individuals, 116 endemic controls (individuals residing in areas where VL is endemic) and 43 nonendemic controls (individuals living in an area where VL is not endemic). We show that, in comparison to the overall IgG Fc N-glycan profiles of asymptomatic or uninfected healthy individuals, those of patients with VL are profoundly altered. These changes correlate with levels of serum cytokines and the inflammation marker C-reactive protein. We also fitted univariate and multivariate ordinal logistic regression models to demonstrate the ability of IgG Fc N-glycosylation features and immunity regulators present in serum to predict disease severity in VL patients. Importantly, we show that Fc N-glycosylation profiles change after treatment of VL. This study introduces important concepts contributing to the understanding of antibody responses in infections with Leishmania parasites and provides new insights into the pathology of human VL. IMPORTANCE: Immunoglobulins (Ig) have been shown to present pro- and anti-inflammatory functions according to the profile of carbohydrates attached to their Fc region. Glycosylation features of serum IgG have been examined in relation to several autoimmune and infectious diseases and provide a mechanistic basis for the protective or pathogenic role of antibodies. Leishmania infantum chagasi is the causative agent of visceral leishmaniasis (VL) in South America, and we show that VL patients produce IgG with patterns of Fc glycans similar to those found in other inflammatory conditions. Specific Fc N-glycosylation features and levels of serum cytokines and C-reactive protein are significantly associated with the development of severe clinical symptoms and, notably, Fc glycosylation changes after treatment. The modifications detected in the N-glycosylation features of IgG Fc from VL patients raise new perspectives on the effector or regulatory role of antibodies in immune responses elicited by infection with Leishmania parasites.

Indexed as

Protein Processing, Post-TranslationalAntibodies, ProtozoanC-Reactive ProteinCytokinesGlycosylationHumansImmunoglobulin Fc FragmentsImmunoglobulin GLeishmaniasis, VisceralAntibodies, ProtozoanC-Reactive ProteinCytokinesImmunoglobulin Fc FragmentsImmunoglobulin G

Identifiers

PMID25467439
PMCPMC4324239
OpenAlexW2115030683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.